Adlai Nortye (ANL) Other Non-Current Assets (2022 - 2023)
Adlai Nortye (ANL) reported Other Non-Current Assets of $24.8 million for Q4 2023, up 7499.08% year-over-year from $327000.0 in Q4 2022, and up 7499.08% quarter-over-quarter from $327000.0 in Q4 2022.
Adlai Nortye (ANL) Other Non-Current Assets (2022 - 2023) Analysis & Trends
Adlai Nortye (ANL) has 2 years of Other Non-Current Assets data on file, last reported at $24.8 million in Q4 2023.
- Other Non-Current Assets for Q4 2023 came in at $24.8 million, up 7499.08% year-over-year; the trailing twelve-month figure through Dec 2023 was $24.8 million (up 7499.08% YoY), and the FY2023 annual result was $24.8 million, up 7499.08% from the prior year.
- Other Non-Current Assets grew to $24.8 million in Q4 2023 per ANL's latest filing, from $327000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $24.8 million in Q4 2023 and troughed at $327000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Adlai Nortye | 21,240.00 | -8.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 24.85 Mn |
| Dec 31, 2022 | 327,000.00 |